Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: selective V-ATPase inhibitors - Reata Pharmaceuticals

Next Previous
Drug Profile

Research programme: selective V-ATPase inhibitors - Reata Pharmaceuticals

Alternative Names: RTA-203

Latest Information Update: 03 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Reata Pharmaceuticals
  • Class Heterocyclic bicyclo compounds
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Feb 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 19 Apr 2006 This programme is still in active development
  • 02 May 2005 Reata Discovery is now called Reata Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top